# Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis

> **NCT03311152** · NA · COMPLETED · sponsor: **Central Hospital, Nancy, France** · enrollment: 529 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Cirrhosis

## Interventions

- **DIAGNOSTIC_TEST:** "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany)

## Key facts

- **NCT ID:** NCT03311152
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-12
- **Primary completion:** 2024-10-17
- **Final completion:** 2024-10-17
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311152, "Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03311152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*